Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Chambers Global Practice Guides – Corporate M&A 2026April 24, 2026Sidley Represents Liberty Mutual in US$750 Million Senior Notes OfferingApril 23, 2026Sidley Represents Valius Sciences in Financing Raising More Than US$10 Million for Future Cancer DiagnosticsApril 23, 2026Japanese Regulator Proposes Strengthened Supervision of Japanese ReinsuranceApril 23, 2026Sidley Represents ModMed in Its Acquisition of Bonsai HealthApril 22, 2026Sidley Represents Cboe Global Markets in Its US$300 Million Sale of Cboe Australia and Cboe Canada to TMX GroupApril 22, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory